- Home
- MOS vs INCY Comparison
MOS vs INCY Comparison
Compare MOS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- INCY
- Stock Information
- Founded
- MOS 1987
- INCY 1991
- Country
- MOS United States
- INCY United States
- Employees
- MOS N/A
- INCY N/A
- Industry
- MOS Agricultural Chemicals
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MOS Industrials
- INCY Health Care
- Exchange
- MOS Nasdaq
- INCY Nasdaq
- Market Cap
- MOS 11.2B
- INCY 13.0B
- IPO Year
- MOS 2004
- INCY 1993
- Fundamental
- Price
- MOS $36.24
- INCY $77.55
- Analyst Decision
- MOS Buy
- INCY Hold
- Analyst Count
- MOS 12
- INCY 20
- Target Price
- MOS $37.00
- INCY $75.81
- AVG Volume (30 Days)
- MOS 4.2M
- INCY 1.6M
- Earning Date
- MOS 08-05-2025
- INCY 07-29-2025
- Dividend Yield
- MOS 2.42%
- INCY N/A
- EPS Growth
- MOS N/A
- INCY 900.04
- EPS
- MOS 1.15
- INCY 4.37
- Revenue
- MOS $11,064,300,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- MOS $18.68
- INCY $13.53
- Revenue Next Year
- MOS N/A
- INCY $10.38
- P/E Ratio
- MOS $31.45
- INCY $17.62
- Revenue Growth
- MOS N/A
- INCY 18.87
- 52 Week Low
- MOS $22.36
- INCY $53.56
- 52 Week High
- MOS $38.23
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- MOS 50.10
- INCY 72.18
- Support Level
- MOS $36.00
- INCY $69.69
- Resistance Level
- MOS $37.53
- INCY $71.29
- Average True Range (ATR)
- MOS 0.88
- INCY 1.86
- MACD
- MOS -0.03
- INCY 0.79
- Stochastic Oscillator
- MOS 54.08
- INCY 89.87
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.